|
Index | - | P/E | - | EPS (ttm) | -0.71 | Insider Own | 0.80% | Shs Outstand | 12.09M | Perf Week | -13.18% |
Market Cap | 24.39M | Forward P/E | - | EPS next Y | -1.01 | Insider Trans | -20.81% | Shs Float | 11.81M | Perf Month | -16.96% |
Income | -7.40M | PEG | - | EPS next Q | -0.20 | Inst Own | 5.30% | Short Float | 5.19% | Perf Quarter | -0.52% |
Sales | 0.80M | P/S | 30.49 | EPS this Y | 63.60% | Inst Trans | -47.28% | Short Ratio | 0.28 | Perf Half Y | 41.48% |
Book/sh | 0.96 | P/B | 1.99 | EPS next Y | -44.30% | ROA | -54.30% | Target Price | - | Perf Year | -14.35% |
Cash/sh | 0.95 | P/C | 2.02 | EPS next 5Y | - | ROE | -59.30% | 52W Range | 1.18 - 3.73 | Perf YTD | -22.67% |
Dividend | - | P/FCF | - | EPS past 5Y | 36.60% | ROI | -67.80% | 52W High | -48.79% | Beta | 0.63 |
Dividend % | - | Quick Ratio | 10.00 | Sales past 5Y | -3.10% | Gross Margin | - | 52W Low | 61.86% | ATR | 0.26 |
Employees | 8 | Current Ratio | 10.00 | Sales Q/Q | 50.00% | Oper. Margin | - | RSI (14) | 32.20 | Volatility | 12.80% 10.38% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 28.80% | Profit Margin | - | Rel Volume | 0.15 | Prev Close | 1.93 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Feb 10 AMC | Payout | - | Avg Volume | 2.22M | Price | 1.91 |
Recom | 2.00 | SMA20 | -24.77% | SMA50 | -22.99% | SMA200 | 2.94% | Volume | 321,750 | Change | -1.04% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite